Clinuvel Pharmaceuticals Limited – OTC:CLVLY
Clinuvel Pharmaceuticals Limited stock price today
Clinuvel Pharmaceuticals Limited stock price monthly change
Clinuvel Pharmaceuticals Limited stock price quarterly change
Clinuvel Pharmaceuticals Limited stock price yearly change
Clinuvel Pharmaceuticals Limited key metrics
Market Cap | 844.91M |
Enterprise value | 451.17M |
P/E | 17.95 |
EV/Sales | 5.14 |
EV/EBITDA | 9.14 |
Price/Sales | 7.23 |
Price/Book | 3.15 |
PEG ratio | 0.11 |
EPS | 0.84 |
Revenue | 126.79M |
EBITDA | 68.18M |
Income | 43.03M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 40.67% |
Oper. margin | 52.5% |
Gross margin | 76.46% |
EBIT margin | 52.5% |
EBITDA margin | 53.78% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeClinuvel Pharmaceuticals Limited stock price history
Clinuvel Pharmaceuticals Limited stock forecast
Clinuvel Pharmaceuticals Limited financial statements
| Sep 2021 | 12.31M | 2.93M | 23.83% |
|---|---|---|---|
| Dec 2021 | 24.63M | 5.87M | 23.83% |
| Jun 2022 | 40.88M | 15.00M | 36.71% |
| Jun 2023 | 48.96M | 19.21M | 39.25% |
| 2026 | 103.01M | 37.42M | 36.32% |
|---|---|---|---|
| 2027 | 306.42M | 125.00M | 40.79% |
Analysts Price target
Financials & Ratios estimates
| Payout ratio | 6.93% |
|---|
| 2020 | 0.1% |
|---|---|
| 2021 | 0.08% |
| 2022 | 0.17% |
| 2023 | 0.22% |
| 2024 | 0.33% |
| Dec 2021 | 115652882 | 7.37M | 6.38% |
|---|---|---|---|
| Sep 2022 | 160292798 | 17.82M | 11.12% |
| Dec 2022 | 160292798 | 21.12M | 13.18% |
| Jun 2023 | 194524790 | 29.89M | 15.37% |
| Jun 2021 | 10.07M | -59.45K | -98.75K |
|---|---|---|---|
| Dec 2021 | 17.32M | -56.44K | -1.38M |
| Jun 2022 | 22.54M | -377.99K | -120.39K |
| Jun 2023 | 15.88M | -632.44K | -94.06K |
Clinuvel Pharmaceuticals Limited other data
| Quarter | Transcript |
|---|---|
| Q2 2023 23 Feb 2024 | Q2 2023 Earnings Call Transcript |
| Q2 2022 24 Feb 2022 | Q2 2022 Earnings Call Transcript |
Monday, 30 September 2024 | ||
| CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP | globenewswire.com | |
Monday, 17 June 2024 | ||
| Afamelanotide in fair-skinned Parkinson's patients | globenewswire.com | |
Thursday, 28 March 2024 | ||
| Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors | globenewswire.com | |
Monday, 4 March 2024 | ||
| Malibu shines a light on CLINUVEL's pioneering work in photomedicine | globenewswire.com | |
Friday, 23 February 2024 | ||
| Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2023 Earnings Call Transcript | Seeking Alpha | |
Thursday, 24 February 2022 | ||
| Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2022 Results - Earnings Call Transcript | Seeking Alpha |
-
What's the price of Clinuvel Pharmaceuticals Limited stock today?
One share of Clinuvel Pharmaceuticals Limited stock can currently be purchased for approximately $8.
-
When is Clinuvel Pharmaceuticals Limited's next earnings date?
Unfortunately, Clinuvel Pharmaceuticals Limited's (CLVLY) next earnings date is currently unknown.
-
Does Clinuvel Pharmaceuticals Limited pay dividends?
Yes, Clinuvel Pharmaceuticals Limited pays dividends and its trailing 12-month yield is 0.43% with 7% payout ratio. The last Clinuvel Pharmaceuticals Limited stock dividend of $0 was paid on 25 Sep 2025.
-
How much money does Clinuvel Pharmaceuticals Limited make?
Clinuvel Pharmaceuticals Limited has a market capitalization of 844.91M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 12.59% to 88.18M US dollars.
-
What is Clinuvel Pharmaceuticals Limited's stock symbol?
Clinuvel Pharmaceuticals Limited is traded on the OTC under the ticker symbol "CLVLY".
-
What is Clinuvel Pharmaceuticals Limited's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Clinuvel Pharmaceuticals Limited?
Shares of Clinuvel Pharmaceuticals Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
When Clinuvel Pharmaceuticals Limited went public?
Clinuvel Pharmaceuticals Limited is publicly traded company for more then 21 years since IPO on 30 Jun 2004.
-
What is Clinuvel Pharmaceuticals Limited's official website?
The official website for Clinuvel Pharmaceuticals Limited is clinuvel.com.
-
Where are Clinuvel Pharmaceuticals Limited's headquarters?
Clinuvel Pharmaceuticals Limited is headquartered at 535 Bourke Street, Melbourne, VIC.
-
How can i contact Clinuvel Pharmaceuticals Limited?
Clinuvel Pharmaceuticals Limited's mailing address is 535 Bourke Street, Melbourne, VIC and company can be reached via phone at +61 3 9660 4900.
Clinuvel Pharmaceuticals Limited company profile:
Clinuvel Pharmaceuticals Limited
clinuvel.comOTC
0
Biotechnology
Healthcare
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Melbourne, VIC 3000
CIK: 0001290877
ISIN: US1887691038
CUSIP: 188769103
